Vivaldi's LAIV technology platform uses the biology of the influenza nonstructural protein 1 (NS1) to provide a new vaccine approach with the potential for superior efficacy and protection. NS1 is a multifunctional virulence factor of the influenza virus. Vivaldi uses proprietary reverse genetics and plasmid rescue technologies to modify the NS1 gene, generating replication-deficient LAIVs attenuated for safety and able to produce a potent, protective immune response.
Research under the CRADA will use Vivaldi's LAIV master strain, which incorporates a specifically truncated NS1 gene and other attenuating genes. The Vivaldi and NIAID teams jointly will select, clone and manipulate H7N9 genes for insertion into Vivaldi's master strain to generate candidate LAIVs against influenza H7N9. Vivaldi and NIAID together will conduct in vitro and in vivo evaluations of the candidate LAIVs, including studies of safety, immunogenicity and protective efficacy in animal models, and will carry out Good Laboratory Practices (GLP) toxicology evaluations of the candidate LAIVs. Data generated in the program are expected to support the filing of an Investigational New Drug (IND) application for a Phase 1 clinical trial in volunteers.
Keywords for this news article include: Chemicals, Chemistry, Pandemics, RNA Viruses, Epidemiology, Viral Vaccines, Orthomyxoviridae, Influenza Vaccines,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Koch Brothers Step up Anti-Obamacare Campaign
- FDIC Sues Big Banks Over Rate Manipulation
- Stocks Close Lower Ahead of Crimea Vote
- Vybz Kartel Convicted of Murder
- SoCalGas Reaches Record Spend on Diversity Suppliers
- U.S. Consumer Sentiment Falls in Early March
- FDIC Accuses Big Banks of Fraud, Conspiracy
- Jittery Investors Dumping Russian Stocks
- Is Malaysian Airlines Flight 370 in Andaman Sea?
- Ulta Shares Look Good on Strong Q4